753 related articles for article (PubMed ID: 31948641)
21. Intensity of statin treatment after acute coronary syndrome, residual risk, and its modification by alirocumab: insights from the ODYSSEY OUTCOMES trial.
Diaz R; Li QH; Bhatt DL; Bittner VA; Baccara-Dinet MT; Goodman SG; Jukema JW; Kimura T; Parkhomenko A; Pordy R; Reiner Ž; Roe MT; Szarek M; Tse HF; White HD; Zahger D; Zeiher AM; Schwartz GG; Steg PG;
Eur J Prev Cardiol; 2021 Mar; 28(1):33-43. PubMed ID: 33755145
[TBL] [Abstract][Full Text] [Related]
22. Effect of alirocumab on major adverse cardiovascular events according to renal function in patients with a recent acute coronary syndrome: prespecified analysis from the ODYSSEY OUTCOMES randomized clinical trial.
Tuñón J; Steg PG; Bhatt DL; Bittner VA; Díaz R; Goodman SG; Jukema JW; Kim YU; Li QH; Mueller C; Parkhomenko A; Pordy R; Sritara P; Szarek M; White HD; Zeiher AM; Schwartz GG;
Eur Heart J; 2020 Nov; 41(42):4114-4123. PubMed ID: 32820320
[TBL] [Abstract][Full Text] [Related]
23. Alirocumab therapy in individuals with type 2 diabetes mellitus and atherosclerotic cardiovascular disease: analysis of the ODYSSEY DM-DYSLIPIDEMIA and DM-INSULIN studies.
Ray KK; Del Prato S; Müller-Wieland D; Cariou B; Colhoun HM; Tinahones FJ; Domenger C; Letierce A; Mandel J; Samuel R; Bujas-Bobanovic M; Leiter LA
Cardiovasc Diabetol; 2019 Nov; 18(1):149. PubMed ID: 31706300
[TBL] [Abstract][Full Text] [Related]
24. Effect of Alirocumab on Stroke in ODYSSEY OUTCOMES.
Jukema JW; Zijlstra LE; Bhatt DL; Bittner VA; Diaz R; Drexel H; Goodman SG; Kim YU; Pordy R; Reiner Ž; Roe MT; Tse HF; Montenegro Valdovinos PC; White HD; Zeiher AM; Szarek M; Schwartz GG; Steg PG;
Circulation; 2019 Dec; 140(25):2054-2062. PubMed ID: 31707788
[TBL] [Abstract][Full Text] [Related]
25. Alirocumab Reduces Total Hospitalizations and Increases Days Alive and Out of Hospital in the ODYSSEY OUTCOMES Trial.
Szarek M; Steg PG; DiCenso D; Bhatt DL; Bittner VA; Budaj A; Diaz R; Goodman SG; Gotcheva N; Jukema JW; Pordy R; Roe MT; Sourdille T; White HD; Xavier D; Zeiher AM; Schwartz GG
Circ Cardiovasc Qual Outcomes; 2019 Nov; 12(11):e005858. PubMed ID: 31707826
[TBL] [Abstract][Full Text] [Related]
26. Effect of Alirocumab on Coronary Atheroma Volume in Japanese Patients With Acute Coronary Syndrome - The ODYSSEY J-IVUS Trial.
Ako J; Hibi K; Tsujita K; Hiro T; Morino Y; Kozuma K; Shinke T; Otake H; Uno K; Louie MJ; Takagi Y; Miyauchi K
Circ J; 2019 Sep; 83(10):2025-2033. PubMed ID: 31434809
[TBL] [Abstract][Full Text] [Related]
27. From lipoprotein apheresis to proprotein convertase subtilisin/kexin type 9 inhibitors: Impact on low-density lipoprotein cholesterol and C-reactive protein levels in cardiovascular disease patients.
Zenti MG; Altomari A; Lupo MG; Botta M; Bonora E; Corsini A; Ruscica M; Ferri N
Eur J Prev Cardiol; 2018 Nov; 25(17):1843-1851. PubMed ID: 30058841
[TBL] [Abstract][Full Text] [Related]
28. Associations between lower levels of low-density lipoprotein cholesterol and cardiovascular events in very high-risk patients: Pooled analysis of nine ODYSSEY trials of alirocumab versus control.
Vallejo-Vaz AJ; Ray KK; Ginsberg HN; Davidson MH; Eckel RH; Lee LV; Bessac L; Pordy R; Letierce A; Cannon CP
Atherosclerosis; 2019 Sep; 288():85-93. PubMed ID: 31349086
[TBL] [Abstract][Full Text] [Related]
29. Proprotein convertase subtilisin/kexin type 9 inhibition after acute coronary syndrome or prior myocardial infarction.
Schwartz GG; Giugliano RP
Curr Opin Lipidol; 2022 Jun; 33(3):147-159. PubMed ID: 35695614
[TBL] [Abstract][Full Text] [Related]
30. Effect of alirocumab on cardiovascular outcomes after acute coronary syndromes according to age: an ODYSSEY OUTCOMES trial analysis.
Sinnaeve PR; Schwartz GG; Wojdyla DM; Alings M; Bhatt DL; Bittner VA; Chiang CE; Correa Flores RM; Diaz R; Dorobantu M; Goodman SG; Jukema JW; Kim YU; Pordy R; Roe MT; Sy RG; Szarek M; White HD; Zeiher AM; Steg PG;
Eur Heart J; 2020 Jun; 41(24):2248-2258. PubMed ID: 31732742
[TBL] [Abstract][Full Text] [Related]
31. Efficacy and safety of alirocumab in patients with or without prior coronary revascularization: Pooled analysis of eight ODYSSEY phase 3 trials.
Kereiakes DJ; Lepor NE; Gerber R; Veronica Lee L; Elassal J; Thompson D; Michael Gibson C
Atherosclerosis; 2018 Oct; 277():211-218. PubMed ID: 30025648
[TBL] [Abstract][Full Text] [Related]
32. Efficacy and safety of alirocumab in Korean patients with hypercholesterolemia and high cardiovascular risk: subanalysis of the ODYSSEY-KT study.
Nam CW; Kim DS; Li J; Baccara-Dinet MT; Li I; Kim JH; Kim CJ
Korean J Intern Med; 2019 Nov; 34(6):1252-1262. PubMed ID: 30257549
[TBL] [Abstract][Full Text] [Related]
33. Efficacy and Safety of Alirocumab in Adults With Homozygous Familial Hypercholesterolemia: The ODYSSEY HoFH Trial.
Blom DJ; Harada-Shiba M; Rubba P; Gaudet D; Kastelein JJP; Charng MJ; Pordy R; Donahue S; Ali S; Dong Y; Khilla N; Banerjee P; Baccara-Dinet M; Rosenson RS
J Am Coll Cardiol; 2020 Jul; 76(2):131-142. PubMed ID: 32646561
[TBL] [Abstract][Full Text] [Related]
34. Effect of alirocumab on cataracts in patients with acute coronary syndromes.
Suc G; Schwartz GG; Goodman SG; Jukema JW; Manvelian G; Poulouin Y; Pordy R; Scemama M; Szarek M; Steg PG;
BMC Ophthalmol; 2023 Jun; 23(1):279. PubMed ID: 37328736
[TBL] [Abstract][Full Text] [Related]
35. Discordant responses of plasma low-density lipoprotein cholesterol and lipoprotein(a) to alirocumab: A pooled analysis from 10 ODYSSEY Phase 3 studies.
Mahmood T; Minnier J; Ito MK; Li QH; Koren A; Kam IW; Fazio S; Shapiro MD
Eur J Prev Cardiol; 2021 Jul; 28(8):816-822. PubMed ID: 34298554
[TBL] [Abstract][Full Text] [Related]
36. Association of Initial and Serial C-Reactive Protein Levels With Adverse Cardiovascular Events and Death After Acute Coronary Syndrome: A Secondary Analysis of the VISTA-16 Trial.
Mani P; Puri R; Schwartz GG; Nissen SE; Shao M; Kastelein JJP; Menon V; Lincoff AM; Nicholls SJ
JAMA Cardiol; 2019 Apr; 4(4):314-320. PubMed ID: 30840024
[TBL] [Abstract][Full Text] [Related]
37. Alirocumab and Cardiovascular Outcomes in Patients With Previous Myocardial Infarction: Prespecified Subanalysis From ODYSSEY OUTCOMES.
Chiang CE; Schwartz GG; Elbez Y; Szarek M; Bhatt DL; Bittner VA; Diaz R; Erglis A; Goodman SG; Hagström E; Jukema JW; Liberopoulos E; Loy M; Pordy R; White HD; Simon T; Steg PG;
Can J Cardiol; 2022 Oct; 38(10):1542-1549. PubMed ID: 35644332
[TBL] [Abstract][Full Text] [Related]
38. Efficacy and safety of the proprotein convertase subtilisin/kexin type 9 inhibitor alirocumab among high cardiovascular risk patients on maximally tolerated statin therapy: The ODYSSEY COMBO I study.
Kereiakes DJ; Robinson JG; Cannon CP; Lorenzato C; Pordy R; Chaudhari U; Colhoun HM
Am Heart J; 2015 Jun; 169(6):906-915.e13. PubMed ID: 26027630
[TBL] [Abstract][Full Text] [Related]
39. Alirocumab after acute coronary syndrome in patients with a history of heart failure.
White HD; Schwartz GG; Szarek M; Bhatt DL; Bittner VA; Chiang CE; Diaz R; Goodman SG; Jukema JW; Loy M; Pagidipati N; Pordy R; Ristić AD; Zeiher AM; Wojdyla DM; Steg PG;
Eur Heart J; 2022 Apr; 43(16):1554-1565. PubMed ID: 34922353
[TBL] [Abstract][Full Text] [Related]
40. Efficacy and safety of alirocumab in reducing lipids and cardiovascular events.
Robinson JG; Farnier M; Krempf M; Bergeron J; Luc G; Averna M; Stroes ES; Langslet G; Raal FJ; El Shahawy M; Koren MJ; Lepor NE; Lorenzato C; Pordy R; Chaudhari U; Kastelein JJ;
N Engl J Med; 2015 Apr; 372(16):1489-99. PubMed ID: 25773378
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
